Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Nanobiotix and keeping the price target at €34.00.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors tied to Nanobiotix’s emerging platform potential and core asset value. He highlights new preclinical findings showing that the company’s Nanoprimer technology can enhance systemic exposure and reduce liver uptake for a wide range of therapeutic modalities, suggesting it could evolve into a broadly applicable delivery platform with future clinical development planned around 2027.

In addition, Ramakanth bases his recommendation on a risk-adjusted net present value assessment of NBTXR3 revenue prospects, incorporating conservative assumptions on discount and terminal growth rates while also factoring in the company’s cash position. He underscores forthcoming clinical milestones in multiple oncology indications and the manufacturing transfer to Johnson & Johnson as value drivers, while acknowledging execution, clinical, commercial, financial, partnership, and intellectual property risks that investors should monitor.